Palisade Bio licenses Giiant Pharma's oral IBD drug candidates GT-2108 and GT-1908

PALISADE BIO, INC.

Exclusive worldwide license for Giiant's targeted prodrug platform; lead asset GT-2108 for ulcerative colitis.
IND/CTA filing for GT-2108 expected by Q3 2024; development supported by $500k Crohn's & Colitis Foundation grant.
Milestone payments (cash or stock at Palisade's election) and royalty payments on sales; Palisade to fund all costs after first IND/CTA approval.
Second program GT-1908 targeting fibrostenotic Crohn's Disease via oral PDE4 compound.

Key facts

Extracted from this filing and checked against the source text.

Material Agreements SEC 8-K Item 1.01/1.02 confidence 0.95

PALISADE BIO, INC. entered into Research Collaboration and License Agreement with Giiant Pharma Inc. valued at The Company is receiving an exclusive worldwide license to develop, manufacture, and commercialize s (effective 2023-09-01).

Action: entry
Agreement: license
Counterparty: Giiant Pharma Inc.
Value: The Company is receiving an exclusive worldwide license to develop, manufacture, and commercialize s
Effective: 2023-09-01

Exact text from the filing

On September 1, 2023 (the “Effective Date”), Palisade Bio, Inc. (the “Company”) entered into a Research Collaboration and License Agreement (the “License Agreement”) with Giiant Pharma Inc. (“Giiant”) whereby the Company is receiving an exclusive (even as the Giiant and its affiliates), worldwide license (with the right to sublicense in multiple tiers) to develop, manufacture, and commercialize substantially all of the assets of Giiant, including: (i) the GT-2018 compound and (ii) the GT-1908 compound and the associated intellectual property around each of the foregoing.

View on SEC.gov

283 material agreements filed in the last 30 days. Browse all material agreements →

PALISADE BIO, INC. filing history →

Source: SEC EDGAR

accession 0001493152-23-032118

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.